Market Research Future (MRFR) has published a research report on the “Global Antiandrogens Market” that contains information from 2018 to 2032. The Antiandrogens market is estimated to register a CAGR of 7.1% from 2023 to 2032.

Antiandrogens Market Highlights

The global antiandrogens market is accounted to register a CAGR of 7.1% during the forecast period and is estimated to reach USD 9.5 billion by 2032.

The pharmaceutical industry's crucial antiandrogens business is centered on drugs made to combat the effects of androgens, or the male sex hormones. These medications are essential for treating various illnesses with aberrant androgen activity. One of the main uses is the treatment of prostate cancer, a common illness that affects men worldwide. Antiandrogens prevent androgens from attaching to their receptors, inhibiting prostate cancer cell development and slowing the spread of the illness. Both steroidal and nonsteroidal antiandrogens are available on the market. Based on the nature of steroid hormones, steroidal antiandrogens have been used for many years. Nonsteroidal antiandrogens have become popular because of their focused activity and minimal side effects. They are frequently created using more contemporary techniques for drug creation. In addition to treating prostate cancer, these drugs effectively treat hirsutism, androgenetic alopecia, and other hormonal diseases, including polycystic ovarian syndrome (PCOS).

Key Players

MRFR recognizes the following companies as the key players in the global antiandrogens market— Pfizer Inc., Astellas Pharma Inc., F. Hoffmann-La Roche Ltd., AstraZeneca Plc, Abbott Laboratories, Takeda Pharmaceutical Company Limited, OSI Pharmaceuticals, Inc., Genentech Inc., Bristol-Myers Squibb Company, Novartis AG, Progenics Pharmaceuticals, Incueensland Nitrates Pty Ltd.

Segment Analysis

The global antiandrogens market has been segmented based type, disease indication and distribution channel.

Based on type, the market is segmented into steroidal and nonsteroidal. The nonsteroidal segment was attributed to holding the largest market share in 2022. This is because several variables, including product approvals, an aging population, and expanded R&D activities, are growing.

The global antiandrogens market has been segmented based on disease indication into prostate cancer, benign prostatic hyperplasia, hirsutism, hyperandrogenism, and others. The prostate cancer segment was expected to hold the largest market share in 2022. the prevalence of prostate cancer worldwide is affected by the aging population, sedentary lifestyles in developed countries, and childhood obesity.

The global antiandrogens market has been segmented based on distribution channels into hospital, retail, and online pharmacies. The online pharmacies segment was expected to hold the largest market share in 2022. Antiandrogens can be ordered by patients from the comfort of their homes and delivered directly to their front door.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Antiandrogens Market Research Report

Regional Analysis

Based on region, the global antiandrogens market has been divided into Asia-Pacific, North America, Europe, and the Rest of the World. North America consists of US and Canada. The Europe Antiandrogens market comprises the UK, Italy, France, Spain, Germany,  and the rest of Europe. The Antiandrogens market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World's Antiandrogens market comprises the Middle East, Africa, and Latin America.

The North American regional sector maintained the largest market share for Antiandrogens. The development of the antiandrogens market in North America is being influenced by several variables that reflect the region's sophisticated healthcare system and changing medical demands. A notable factor driving the need for antiandrogen therapy is the frequency of prostate cancer, a disease strongly impacted by androgens. In North America, prostate cancer is a major public health problem, and this market has grown as people become more aware of the value of early detection and treatment.

Moreover, the Europe market has been persistently growing over the forecast period. Another crucial factor is the European regulatory environment. Thanks to strict yet clear restrictions, only safe and effective antiandrogens are authorized for usage. As a result, there is an increase in patient confidence and trust in these drugs, leading to better adoption rates. The demand for antiandrogen medicines has also been driven by public health campaigns and organizations that try to increase awareness of illnesses like prostate cancer and encourage early detection and treatment.

Public health education and awareness programs have also become more popular in Asia. These campaigns stress the value of early identification and treatment to increase public awareness of diseases like prostate cancer. Because of this, more people are seeking medical care, which results in more diagnoses and a consequent rise in demand for antiandrogen therapy.

Furthermore, the rest of the world's antiandrogens market is divided into the Middle East, Africa, and Latin America. To promote early detection and treatment, these initiatives seek to increase public knowledge of diseases, including hormonal imbalances and prostate cancer. Because of this, more people are seeking medical care, which results in more diagnoses and a consequent rise in demand for antiandrogen therapy.

Key Findings of the Study

• The global antiandrogens market is expected to reach USD 9.5 billion by 2032, at a CAGR of 7.1% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market due to advanced antiandrogen drugs have been introduced as a result of expanding medical research and development spending and bettering healthcare infrastructure.


• Based on distribution channel, the online pharmacies segment was attributed to holding the largest market in 2022, with an approximate market share of 45–65%.


• Pfizer Inc., Astellas Pharma Inc., F. Hoffmann-La Roche Ltd., AstraZeneca Plc, Abbott Laboratories, Takeda Pharmaceutical Company Limited, OSI Pharmaceuticals, Inc., Genentech Inc., Bristol-Myers Squibb Company, Novartis AG, Progenics Pharmaceuticals, Incueensland Nitrates Pty Ltd.